Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients

Clinical and Experimental Immunology

Volumn 180, Issue 2, 2015, Pages 280-288

  Gey, A ^a,b   Tadie, J M ^a,c,f,g,h   Caumont Prim, A ^a,e   Hauw Berlemont, C ^a,c   Cynober, L ^b,c   Fagon, J Y ^a,c   Terme, M ^d   Diehl, J L ^a,c   Delclaux, C ^a,c   Tartour, E ^a,d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^e Unité d'Épidémiologie et de Recherche Clinique   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE RENNES 1   (France)

^h UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Arginine; Biomarker; Critically ill patients; Granulocytic myeloid derived suppressor cells (gMDSC); Immunosuppression

Indexed keywords

ARGINASE; ARGININE; CITRULLINE; INTERLEUKIN 10; PROSTAGLANDIN E2; IL10 PROTEIN, HUMAN; NITRIC OXIDE;

ADULT; ARTICLE; BODY MASS; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GRANULOCYTE; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; INTENSIVE CARE UNIT; MONOCYTE; MORTALITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PLASMA; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SUPPRESSOR CELL; AGED; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; FEMALE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY;

ADULT; AGED; ARGINASE; ARGININE; CRITICAL ILLNESS; DINOPROSTONE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; INTERLEUKIN-10; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; NITRIC OXIDE;

EID: 84927583007     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12567     Document Type: Article

References (51)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-174.
2. Peranzoni E, Zilio S, Marigo I etal. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-244.
3. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-268.
4. Tartour E, Pere H, Maillere B etal. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30:83-95.
5. Atochina O, Daly-Engel T, Piskorska D, McGuire E, Harn DA. A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism. J Immunol 2001; 167:4293-4302.
6. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006; 176:2085-2094.
7. Mencacci A, Montagnoli C, Bacci A etal. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol 2002; 169:3180-3190.
8. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32:19-25.
9. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-191.
10. Tadmor T, Attias D, Polliack A. Myeloid-derived suppressor cells - their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 2011; 153:557-567.
11. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC etal. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011; 71:5101-5110.
12. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998; 160:5729-5734.
13. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012; 381:14-22.
14. Zea AH, Rodriguez PC, Atkins MB etal. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-3048.
15. Lu T, Gabrilovich DI. Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res 2012; 18:4877-4882.
16. Raber PL, Thevenot P, Sierra R etal. Subpopulations of myeloid-derived suppressor cells (MDSC) impair T cell responses through independent nitric oxide-related pathways. Int J Cancer 2013; 134:2853-2864.
17. Kao CC, Bandi V, Guntupalli KK, Wu M, Castillo L, Jahoor F. Arginine, citrulline and nitric oxide metabolism in sepsis. Clin Sci (Lond) 2009; 117:23-30.
18. Druml W, Heinzel G, Kleinberger G. Amino acid kinetics in patients with sepsis. Am J Clin Nutr 2001; 73:908-913.
19. van Waardenburg DA, de Betue CT, Luiking YC, Engel M, Deutz NE. Plasma arginine and citrulline concentrations in critically ill children: strong relation with inflammation. Am J Clin Nutr 2007; 86:1438-1444.
20. Villalpando S, Gopal J, Balasubramanyam A, Bandi VP, Guntupalli K, Jahoor F. In vivo arginine production and intravascular nitric oxide synthesis in hypotensive sepsis. Am J Clin Nutr 2006; 84:197-203.
21. Tadie JM, Cynober L, Peigne V etal. Arginine administration to critically ill patients with a low nitric oxide fraction in the airways: a pilot study. Intensive Care Med 2013; 39:1663-1665.
22. Stephan F, Yang K, Tankovic J etal. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 2002; 30:315-322.
23. Fricke I, Mirza N, Dupont J etal. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007; 13:4840-4848.
24. Ko JS, Zea AH, Rini BI etal. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-2157.
25. Badoual C, Hans S, Merillon N etal. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-138.
26. Loi C, Zazzo JF, Delpierre E etal. Increasing plasma glutamine in postoperative patients fed an arginine-rich immune-enhancing diet - a pharmacokinetic randomized controlled study. Crit Care Med 2009; 37:501-509.
27. Tadie JM, Trinquart L, Janniere-Nartey C etal. Prediction of nosocomial infection acquisition in ventilated patients by nasal nitric oxide: proof-of-concept study. Shock 2010; 34:217-221.
28. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-5802.
29. Rodriguez PC, Ernstoff MS, Hernandez C etal. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69:1553-1560.
30. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13:721s-726.
31. Bune AJ, Shergill JK, Cammack R, Cook HT. L-arginine depletion by arginase reduces nitric oxide production in endotoxic shock: an electron paramagnetic resonance study. FEBS Lett 1995; 366:127-130.
32. Curis E, Nicolis I, Moinard C etal. Almost all about citrulline in mammals. Amino Acids 2005; 29:177-205.
33. Cynober L. Citrulline: just a biomarker or a conditionally essential amino acid and a pharmaconutrient in critically ill patients? Crit Care 2013; 17:122.
34. Piton G, Belon F, Cypriani B etal. Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality. Crit Care Med 2013; 41:2169-2176.
35. Rouge C, Des Robert C, Robins A etal. Manipulation of citrulline availability in humans. Am J Physiol Gastrointest Liver Physiol 2007; 293:G1061-1067.
36. Cynober L. Potential interest of citrulline in critically ill patients. Reanimation 2013; 22:350-357.
37. Langouche L, Marques MB, Ingels C etal. Critical illness induces alternative activation of M2 macrophages in adipose tissue. Crit Care 2011; 15:R245.
38. Oberholzer A, Oberholzer C, Moldawer LL. Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit Care Med 2000; 28 (Suppl. 4):N3-12.
39. Paterson RL, Galley HF, Dhillon JK, Webster NR. Increased nuclear factor kappa B activation in critically ill patients who die. Crit Care Med 2000; 28:1047-1051.
40. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71:7463-7470.
41. Mundy-Bosse BL, Young GS, Bauer T etal. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol Immunother 2011; 60:1269-1279.
42. Corzo CA, Cotter MJ, Cheng P etal. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-5701.
43. Sander LE, Sackett SD, Dierssen U etal. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010; 207:1453-1464.
44. Movahedi K, Guilliams M, Van den Bossche J etal. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-4244.
45. Nierhaus A, Klatte S, Linssen J etal. Revisiting the white blood cell count: immature granulocytes count as a diagnostic marker to discriminate between SIRS and sepsis - a prospective, observational study. BMC Immunol 2013; 14:8.
46. Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med 2003; 29:1245-1252.
47. Darcy CJ, Minigo G, Piera KA etal. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care 2014; 18:R163.
48. Gibot S, Bene MC, Noel R etal. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012; 186:65-71.
49. Frazier WJ, Hall MW. Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin N Am 2008; 55:647-668, xi.
50. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008; 34:1980-1990.
51. Ugel S, Delpozzo F, Desantis G etal. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9:470-481.